Risperidone and Paliperidone Inhibit P-Glycoprotein Activity *In Vitro*

Hao-Jie Zhu¹, Jun-Sheng Wang², John S Markowitz¹, Jennifer L Donovan², Bryan B Gibson² and C Lindsay DeVane^{*2}

¹Laboratory of Drug Disposition and Pharmacogenetics, Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, SC, USA; ²Laboratory of Drug Disposition and Pharmacogenetics, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA

Risperidone (RSP) and its major active metabolite, 9-hydroxy-risperidone (paliperidone, PALI), are substrates of the drug transporter P-glycoprotein (P-gp). The goal of this study was to examine the *in vitro* effects of RSP and PALI on P-gp-mediated transport. The intracellular accumulation of rhodamine 123 (Rh123) and doxorubicin (DOX) were examined in LLC-PK1/MDR1 cells to evaluate P-gp inhibition by RSP and PALI. Both compounds significantly increased the intracellular accumulation of Rh123 and DOX in a concentration-dependent manner. The IC₅₀ values of RSP for inhibiting P-gp-mediated transport of Rh123 and DOX were 63.26 and 15.78 μ M, respectively, whereas the IC₅₀ values of PALI were > 100 μ M, indicating that PALI is a less potent P-gp inhibitor. Caco-2 and primary cultured rat brain microvessel endothelial cells (RBMECs) were utilized to investigate the possible influence of RSP on intestinal absorption and blood–brain barrier (BBB) transport of coadministered drugs that are P-gp substrates. RSP, 1–50 μ M, significantly enhanced the intracellular accumulation of Rh123 in Caco-2 cells by inhibiting P-gp activity with an IC₅₀ value of 5.87 μ M. Following exposure to 10 μ M RSP, the apparent permeability coefficient of Rh123 across Caco-2 and RBMECs monolayers was increased to 2.02 and 2.63-fold in the apical to basolateral direction, but decreased to 0.37 and 0.21-fold in the basolateral to apical direction, respectively. These data suggest that RSP and PALI, to a lesser extent, have a potential to influence the pharmacokinetics and hence the pharmacodynamics of coadministered drugs via inhibition of P-gp-mediated transport. However, no human data exist that address this issue. In particular, RSP may interact with its own active metabolite PALI by promoting its brain concentration through inhibiting P-gp-mediated efflux of PALI across endothelial cells of the BBB.

Neuropsychopharmacology (2007) 32, 757–764. doi:10.1038/sj.npp.1301181; published online 23 August 2006

Keywords: risperidone; paliperidone; P-glycoprotein; transporter; blood–brain barrier; drug–drug interaction

INTRODUCTION

P-glycoprotein (ABCB1, MDR1, P-gp) is an ATP-dependent efflux transporter (Ayrton and Morgan, 2001; Mizuno *et al*, 2003). In addition to its expression in multidrug resistance tumor cells, the distribution of P-gp includes the epithelial cells lining the luminal surface of enterocytes in the small intestine, the canalicular surface of hepatocytes, the apical surface of epithelial cells of proximal renal tubules, epithelial cells of placenta on the maternal blood flow side, and the luminal surface of capillary endothelial cells comprising the blood–brain barrier (BBB) (Cordon-Cardo *et al*, 1989; Lieberman *et al*, 1989; Fardel *et al*, 1993;

Gatmaitan and Arias, 1993; Bendayan *et al*, 2002). It is becoming increasingly apparent that P-gp plays an important role in the disposition of numerous structurally diverse drugs that are its substrates (Benet *et al*, 1999). For example, owing to its active efflux, P-gp limits the intestinal absorption of cyclosporine, ivermectin, and paclitaxel after oral dosing (Sparreboom *et al*, 1997; Kwei *et al*, 1999). We and others have shown that P-gp limits the brain penetration in animals of a number of centrally active drugs including risperidone (RSP), its active metabolite 9-hydroxy-risperidone (paliperidone, PALI), methadone, olanzapine, and others (Aquilante *et al*, 2000; Wang *et al*, 2004a,b,c). The anatomical localization of P-gp implies it plays a critical role in protecting cells and organs from exposure to xenobiotics. However, P-gp also limits a variety of medications from reaching their therapeutic target(s) thereby preventing or minimizing pharmacological effects. Thus, the status as P-gp substrates of lead compounds in drug development may influence the choice of formulation, route of administration, and dose necessary to achieve

*Correspondence: Dr CL DeVane, Laboratory of Drug Disposition and Pharmacogenetics, Medical University of South Carolina, 173 Ashley Avenue, Room 405B, Charleston, SC 29425, USA, Tel: +1 843 792 5448, Fax: +1 843 792 6318, E-mail: devaneL@musc.edu
Received 9 February 2006; revised 23 June 2006; accepted 1 July 2006
Online publication: 12 July 2006 at <http://www.acnp.org/citations/Npp071206060082/default.pdf>

desired effects (Mizuno *et al*, 2003). The potential for drug-drug interactions arises when the P-gp substrate is also an inhibitor of P-gp or is coadministered with an inhibitor (Lin, 2003).

RSP is one of the most commonly used atypical antipsychotics. Its major route of elimination is oxidation via hepatic CYP2D6 to 9-hydroxy-risperidone (DeVane and Markowitz, 2000). This active metabolite, also known as paliperidone (PALI), is currently in development as a separate antipsychotic drug (Seeman, 2005). RSP and PALI have similar binding affinities for several receptors thought to be important for antipsychotic efficacy and a favorable adverse event profile (Schotte *et al*, 1993, 1996). The K_i values for binding to the dopamine D_2 and 5HT $_{2A}$ receptor subtype for RSP and PALI were 5.9 and 4.8 nM, and 0.16 and 0.25 nM, respectively. However, the off-rate for dissociation from human cloned D_2 receptor is faster for PALI (60 s) compared to RSP (27 min) (Seeman, 2005). By using the P-gp knockout mouse model, we and others have demonstrated that both RSP and PALI are P-gp substrates and their entry into the brain is dramatically limited by P-gp in the BBB (Wang *et al*, 2004a; Doran *et al*, 2005). Following intraperitoneal (i.p.) dosing, brain concentrations of RSP and PALI in knockout mice were more than 10-fold higher than that in wild-type mice, whereas plasma revealed no significant differences in concentrations.

It is well known that some P-gp substrates (eg verapamil, quinidine, etc) are also potent P-gp inhibitors (Sadeque *et al*, 2000). Coadministration of these inhibitors may result in the alteration of the pharmacokinetics of other drugs that are P-gp substrates (Kharasch *et al*, 2004; Nakagami *et al*, 2005). Recent studies have demonstrated that RSP increased the intracellular accumulation of P-gp substrates rhodamine123 (Rh123) and calcein-AM in bovine brain microvessel endothelial cells and MDR1 gene transfected MDCK cells, respectively, indicating that RSP is a potential P-gp inhibitor (Mahar Doan *et al*, 2002; Bachmeier and Miller, 2005). However, the possible effects of RSP on the disposition of coadministered drugs through P-gp inhibition remain unknown. Our recent study indicated that RSP significantly increased brain concentrations of sertraline and its metabolite desmethylsertraline in a mouse model without significantly altering their plasma concentrations at 1 h after i.p. injection (Wang *et al*, 2006a). Based upon a P-gp ATPase activity assay, we have demonstrated that sertraline and desmethylsertraline have high affinity for P-gp indicating that both compounds are potential P-gp substrates (Wang *et al*, 2006b). Therefore, the increases of sertraline and desmethylsertraline brain concentrations might be caused by the inhibition of P-gp in BBB by RSP.

In this study, the inhibitory effects of RSP and PALI on P-gp activity were investigated utilizing the P-gp overexpressing cell line LLC-PK1/MDR1. Furthermore, the monolayers of Caco-2 and primary cultured rat brain microvessel endothelial cells (RBMECs) served as small intestine and BBB *in vitro* models, respectively, to evaluate the possible influence of RSP on the absorption and BBB transport of drugs that are P-gp substrates. This report provides the first data, to our knowledge, documenting the P-gp inhibitory properties of PALI and the potential influence of RSP on the disposition of drugs that are P-gp substrates through P-gp inhibition.

MATERIALS AND METHODS

Materials

The pig kidney epithelial cell line LLC-PK1 and its P-gp overexpressing mutant LLC-PK1/MDR1 cells were generously provided by Dr Kari Kivistö (Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany). The human colon adenocarcinoma cell line Caco-2 at passage 17 was purchased from American Type Culture Collection (Manassas, VA) and was used for experiments from passages 35 to 45. Fetal bovine serum and Dulbecco's modified Eagle's medium (DMEM) containing 4500 mg/l glucose, 4 mM L-glutamine, and sodium pyruvate were purchased from Hyclone Co. (Logan, UT). Collagenase II was obtained from Worthington Biochemical Co. (Lakewood, NJ) and dispase from BD Bioscience (Bedford, MA). MEM nonessential amino acid solution was obtained from Stemcell Technologies Inc. (Vancouver, British Columbia, Canada) whereas trypsin, Dulbecco's phosphate-buffered saline (DPBS), penicillin, and streptomycin were all purchased from Mediatech Inc. (Herndon, VA). Doxorubicin (DOX) and Rh123 were obtained from Sigma Co. (St Louis, MO). RSP and PALI were donated by Janssen Pharmaceuticals (Titusville, NJ). Valspodar (PSC833) was a gift from Novartis Pharmaceuticals (Basel, Switzerland). All other drugs and reagents were of analytical grade and commercially available.

Cell Cultures

LLC-PK1, LLC-PK1/MDR1, and Caco-2 cells. LLC-PK1 and Caco-2 cells were cultured at 37°C in DMEM supplemented with 10% fetal bovine serum, 1% MEM nonessential amino acids, 100 U/ml penicillin, and 100 µg/ml streptomycin in an atmosphere of 5% CO $_2$ and 95% relative humidity. LLC-PK1/MDR1 cells were cultured under the same conditions with the exception of the addition of 640 nM of vincristine which was added to the culture medium to maintain P-gp expression (Smit *et al*, 1998).

For Rh123 and DOX intracellular accumulation experiments, cells were seeded at a density of 1×10^5 cells/ml/well in 24-well plates. Culture medium was replaced every 2 days until cells reached confluence.

For transport experiments, Caco-2 cells were seeded onto polyester membrane filters (0.4 µm pores, 4.7 cm 2 growth area, Corning Inc., Corning, NY) of Transwell inserts at a density of 1×10^5 cells/cm 2 . Culture medium was likewise changed every 2 days. Transepithelial electric resistance (TEER) of RBMECs monolayers was monitored before transport studies using an EVOMeter fitted with chopstick electrodes (World Precision Instruments, Sarasota, FL), and the monolayers with TEER of greater than 500 Ω cm 2 were utilized for the transport studies.

Primary culture of rat brain microvessel endothelial cells. RBMECs were isolated according to the modified method of Abbott *et al* (1992). Briefly, the cerebral cortex was obtained from 10–15-day-old rats and washed 3 times with ice-cold DPBS. After surface vessels and meninges were removed, cortex gray matter was minced and incubated at 37°C for 1 h in serum-free DMEM containing 20 U/ml Dnase I and 0.1% collagenase II/dispase. After

digestion, the enzyme mixture was triturated with a Pasteur pipette, then centrifuged at 800g for 5 min. The resultant pellet was resuspended in DPBS containing 25% bovine serum albumin (BSA) and centrifuged at 2000g at 4°C for 10 min to remove fat, cell debris, and myelin that were floating on the BSA solution. The pellet containing microvessels was resuspended and incubated in serum-free DMEM containing 0.1% collagenase II at 37°C for 30 min for a second digestion that served to remove the microvessel basement membrane. Released endothelial cells were further purified by centrifugation over a 50% Percoll gradient. The cells were maintained in DMEM supplemented with 20% fetal bovine serum, penicillin 100 kU/l, and streptomycin 100 mg/l.

For transport experiments, RBMECs were applied to polyester transwell membranes (0.4 µm pore size; 4.7 cm² growth area; Corning Inc., Corning, NY) at a density of 1×10^5 /cm². Culture medium was changed every 3 days. The monolayers with TEER of greater than 250 Ω cm² were utilized for the transport studies.

Intracellular Rh123 and DOX Accumulation Studies

Intracellular accumulation of P-gp substrates Rh123 and DOX were measured to evaluate the P-gp activity in LLC-PK1/MDR1 and Caco-2 cells whereas LLC-PK1 was included as a negative control (van der Sandt *et al*, 2000). After reaching confluence, cells were preincubated at 37°C for 30 min with transport buffer (serum-free DMEM containing 25 mM N-2-hydroxyl piperazine-N'-2-ehane sulfonic acid, pH 7.4). Vehicle control (0.5% dimethylsulfoxide (DMSO)), specific concentrations of RSP, PALI, or PSC833 were added, then 5 µM of Rh123 or 10 µM of DOX were added for an additional 60 min incubation. After incubation, the solutions were discarded, and the cells were washed three times with ice-cold DPBS and solubilized with 1% Triton X-100. The fluorescence of Rh123 and DOX were measured by high-performance liquid chromatography (HPLC) assay. The concentrations were determined from the fluorescence value through the construction of Rh123 and DOX standard curves. The amount of Rh123 or DOX in each sample was standardized with the protein content as determined by the Lowry assay.

Rh123 Transport Studies

When RBMECs or Caco-2 cells reached confluence, the integrity of monolayers was checked by both TEER value and the transport rate of fluorescein, a recognized paracellular transport marker (van Bree *et al*, 1988). The qualified monolayers were rinsed two times with DPBS and preincubated with transport buffer at 37°C for 30 min. In all, 0.5% DMSO, RSP, or PSC833 was loaded at both sides of the monolayers, then Rh123 (5 µM) was added into the basolateral side for the basolateral to apical (B-A) transport study or apical side for the apical to basolateral (A-B) transport study. At designated times, 150 µl samples were taken from the receiver compartment, and the same volume of receiver compartment solution was replaced immediately after each sampling. Concentrations of Rh123 were determined by HPLC. Apparent permeability coefficients, P_{app} (cm/s) were calculated according to the

following equation:

$$P_{app} = \frac{dQ}{dt} (C^{-1} A^{-1})$$

where dQ/dt is the rate at which the Rh123 appears in the receiver compartment, A is the diffusion area (cm²), and C is the initial concentration of Rh123 in the donor compartment.

HPLC Analysis

An established HPLC assay was utilized for the quantitative analysis of Rh123 and DOX. The HPLC system consisted of a Waters 2690 Separations module (Waters, Milford, MA), a C18 reversed-phase column (300 × 4.1 mm i.d., Versoack, Alltech, Deerfield, IL), and a Waters 474 scanning fluorescence detector (Waters, Milford, MA). The separation of Rh123 was carried out isocratically using 20 mM of sodium acetate buffer (pH 4.0):acetonitrile (40:60, v:v) at a flow rate of 1.0 ml/min. The mobile phase for DOX samples consisted of a 50 mM NaH₂PO₄ buffer (pH3.0):acetonitrile (69:31, v:v) mixture with a flow rate of 1.0 ml/min. The detection wavelengths were 488 nm (λ_{ex}), 535 nm (λ_{em}) for Rh123, and 480 nm (λ_{ex}), 560 nm (λ_{em}) for DOX.

Statistical Analysis

Statistical analysis for significant differences was performed using the two-tailed Student's *t*-test. A *p*-value of 0.05 or less was considered to be statistically significant. Data were calculated as mean ± SD for display in tables and figures.

RESULTS

RSP and PALI Increased the Intracellular Accumulation of Rh123 and DOX

By using Rh123 and DOX exclusion assay, RSP and PALI were evaluated for their potential inhibitory effects on P-gp efflux. Both RSP and PALI significantly increased the intracellular accumulation of Rh123 and DOX in LLC-PK1/MDR1 cells in a concentration-dependent manner (Figure 1a and b). An IC₅₀ value of 63.26 µM was obtained for the inhibition of Rh123 efflux by RSP and 15.78 µM was recorded for DOX. At concentrations of 50 and 100 µM, PALI significantly increased the intracellular accumulation of Rh123 and DOX. However, this compound had much lower potency than RSP for inhibiting P-gp efflux activity, and its IC₅₀ values were >100 µM for inhibiting P-gp-mediated transport of both Rh123 and DOX. PALI, even at tested concentrations as high as 100 µM, did not increase substrate accumulation to levels approaching that of the positive control (PSC833 2 µM) in both Rh123 and DOX accumulation assays. Only when DOX, not Rh123, was used as P-gp substrate, the inhibitory effect of RSP (100 µM) was comparable with that of PSC833 (2 µM) (*p* > 0.05). With regard to P-gp negative LLC-PK1 cells, neither RSP nor PALI, at concentrations of 100 µM, had any significant influence on the intracellular accumulation of Rh123 or DOX.

Similar experiments were also conducted to evaluate the inhibitory effect of RSP on P-gp activity in another P-gp

Figure 1 Effect of RSP and PALI on the intracellular accumulation of Rh123 (a) and DOX (b) in LLC-PK1/MDR1 cells. The intracellular accumulation of Rh123 (5 μ M) and DOX (10 μ M) in LLC-PK1/MDR1 cells after 1 h incubation in the presence or absence of RSP (1, 5, 10, 50, 100 μ M), PALI (1, 5, 10, 50, 100 μ M), or PSC833 (2 μ M) was determined as described in the Materials and Methods section. LLC-PK1 cells were also included as the negative control. Each data value is the mean with a bar representing SD, $n = 4$. * $p < 0.05$ vs control, ** $p < 0.01$ vs control.

expressing cell line, Caco-2 cells. At concentrations ranging from 1 to 50 μ M, RSP significantly enhanced the intracellular accumulation of Rh123 in a concentration-dependent manner through P-gp inhibition with an IC_{50} value of 5.87 μ M (Figure 2).

Effect of RSP on the Transport of Rh123 across Caco-2 and RBMECs Monolayers

Caco-2 and RBMECs monolayers were utilized in this study as *in vitro* models to investigate the influence of RSP on intestinal absorption and BBB entry of P-gp substrate, respectively. As shown in Table 1, Rh123 exhibited highly polarized transport across Caco-2 and RBMECs monolayers (ie $P_{app\ B-A} \gg P_{app\ A-B}$). In the presence of 10 μ M of RSP, the transport of Rh123 was significantly decreased in the B-A direction but increased in the A-B direction in both Caco-2 and RBMECs monolayers (Figures 3 and 4). In Caco-2 cells, the P_{app} value was decreased by 62.9% in the B-A direction and increased by 102.2% in the A-B direction in the presence of 10 μ M RSP. Regarding RBMECs, the treatment

Figure 2 Effect of RSP on the intracellular accumulation of Rh123 in Caco-2 cells. Inhibitory effect of RSP on P-gp function in Caco-2 cells was assessed by measuring the intracellular concentrations of Rh123 after incubation for 1 h in the absence or presence of RSP (1, 5, 10, 50 μ M). Each data value is the mean with a bar representing SD, $n = 4$. * $p < 0.05$ vs control, ** $p < 0.01$ vs control.

of 10 μ M of RSP resulted in a 79.3% decrease of Rh123 $P_{app\ B-A}$ value and 162.5% increase of Rh123 $P_{app\ A-B}$ value. The positive control (PSC833, 2 μ M) produced a similar

Figure 3 Effect of RSP on the directional transport of Rh123 across Caco-2 cell monolayers. Rh123 (5 µM) was added to the basolateral (for B-A transport, a) or apical side (for A-B transport, b) of Caco-2 cell monolayers, whereas RSP (1, 10 µM) or PSC833 (2 µM) was added to both sides of monolayers. The amounts of Rh123 in the receiver compartment were determined at 30, 60, 90, 120 min after incubation. Each point represents the mean $\pm$ SD of three experiments.

Table 1 Effect of RSP on Apparent Permeability Coefficients (P_{app}) of Rh123 (5 µM) across Caco-2 Cells and RBMECs Monolayers

Cell	Inhibitor	P_{app} ($\text{cm s}^{-1} \times 10^{-7}$)		Ratio ($P_{app \text{ B-A}} / P_{app \text{ A-B}}$)
		B-A	A-B	
Caco-2	Control	18.68 $\pm$ 0.78	1.80 $\pm$ 0.34	10.38
	1 µM RSP	18.34 $\pm$ 3.41	2.19 $\pm$ 0.31	8.37
	10 µM RSP	6.93 $\pm$ 0.94**	3.64 $\pm$ 0.41**	1.90
	2 µM PSC833	3.91 $\pm$ 0.85**	2.96 $\pm$ 0.22**	1.32
RBMECs	Control	35.04 $\pm$ 4.39	1.20 $\pm$ 0.06	29.20
	10 µM RSP	7.26 $\pm$ 0.58**	3.15 $\pm$ 0.25**	2.30
	2 µM PSC833	9.74 $\pm$ 0.42**	2.97 $\pm$ 0.33**	3.28

Results are reported as mean $\pm$ SD, $n = 3$.

** $p < 0.01$ vs control.

Figure 4 Effect of RSP on the directional transport of Rh123 across the RBMECs monolayers. Rh123 (5 µM) was added to the donor compartment, whereas RSP (10 µM) or PSC833 (2 µM) was added to both the apical and basolateral compartment. After 30, 60, 90, 120 min incubation, concentration of Rh123 in receiver compartment was determined to assess Rh123 transport in both B-A (a) and A-B (b) directions. Each point represents the mean with a bar representing SD of three experiments.

effect on P-gp-mediated Rh123 transport across Caco-2 and RBMECs monolayers. In the A-B direction, 10 µM RSP increased Rh123 $P_{app \text{ A-B}}$ value to levels equivalent to 2 µM PSC833 in both Caco-2 and RBMECs monolayers ($p > 0.05$). In the B-A direction, 10 µM RSP exhibited a significantly higher effect in decreasing Rh123 transport across RBMECs monolayers than 2 µM PSC833 ($p < 0.05$), but less across Caco-2 monolayers ($p < 0.05$).

DISCUSSION

A previous *in vitro* study by our group using an ATPase activity assay provided some of first evidence that several atypical antipsychotic drugs, that is, quetiapine, olanzapine, and RSP, exhibited high affinity for P-gp (Boulton *et al*, 2002). Subsequent *in vivo* studies in P-gp knockout mouse models by our group and others revealed that brain concentration, and ratio of brain-to-plasma concentrations of RSP and its major metabolite, PALI, were significantly higher in knockout mice vs wild-type animals (Wang *et al*, 2004a; Doran *et al*, 2005). These results indicated that both RSP and PALI are substrates of P-gp and that their disposition might be influenced by the functional

status of P-gp. Furthermore, RSP has been reported to be a potential P-gp inhibitor by increasing the intracellular accumulation of the P-gp substrates Rh123 and calcein-AM in bovine brain microvessel endothelial cells and MDCKII-MDR1 cells, respectively (Mahar Doan *et al*, 2002; Bachmeier and Miller, 2005). This possibility also offers the unique opportunity for RSP to influence the brain accumulation of PALI when the latter compound is formed *in vivo* from RSP administration than in comparison to separate administration as a pre-formed metabolite alone. No published data are available on the status of PALI as a P-gp inhibitor.

In our current study, the MDR1 gene transfected cell line LLC-PK1/MDR1 was used to evaluate the inhibitory effect of both RSP and PALI on P-gp activity. The parental cell line LLC-PK1 was included as a negative control. The results demonstrated that both RSP and PALI increased the intracellular accumulation of Rh123 and DOX in LLC-PK1/MDR1 cells in a concentration-dependent manner, with RSP exhibiting a much higher potency than PALI. The increments of Rh123 and DOX caused by 100 μ M RSP were 3.8 and 2.2-fold higher, respectively, than that caused by 100 μ M of PALI. As a comparison, in P-gp-negative LLC-PK1 cells, both RSP and PALI did not alter the intracellular accumulation of Rh123 and DOX. As P-gp expression is generally viewed as the only functional difference between LLC-PK1 and LLC-PK1/MDR1 cells, these data suggest that the mechanism by which RSP and PALI increased Rh123 and DOX intracellular accumulation is through inhibition of P-gp-mediated efflux. Owing to the relatively weak inhibitory effects observed with PALI, further experiments using Caco-2 and RBMECs models were only conducted with RSP.

The intestinal epithelial cell line Caco-2 is one of the most commonly used *in vitro* models for prediction of intestinal drug absorption. A variety of transporters including P-gp are functionally expressed in Caco-2 cells (Hunter *et al*, 1993). Co-administration of RSP at concentrations from 1 to 50 μ M with Rh123 resulted in significant increases of the intracellular accumulation of Rh123 in a concentration-dependent manner. Owing to the apical localization and directional transport of P-gp in Caco-2 monolayers, the P_{app} value of Rh123 in the B–A direction was approximately 10-fold of that in the A–B direction under our experimental conditions. This effect of RSP on the transport of Rh123 across Caco-2 monolayers is in agreement with its P-gp inhibitory activity. The transport of Rh123 was significantly decreased in B–A direction, but increased in A–B direction by the coadministration of 10 μ M RSP.

To date, several cell culture systems have been established as *in vitro* BBB model (Terasaki *et al*, 2003). Given the localized expression of P-gp, primary cultured brain microvessel endothelial cells have been widely used for the investigation of P-gp-mediated transport across BBB (Loscher and Potschka, 2005). In this study, the potential influence of RSP on the P-gp-mediated drug transport through BBB was evaluated using primary cultured RBMECs monolayers. The results indicated that 10 μ M of RSP significantly inhibited P-gp efflux and decreased Rh123 transport in the B–A direction but increased transport in the reverse direction, a finding consistent with the observations in the Caco-2 monolayers experiment previously discussed.

As more therapeutic agents have been demonstrated to be P-gp substrates and/or inhibitors, there is increasing evidence for P-gp-mediated drug–drug interactions (Baillyssac *et al*, 2005). It is well known that the intestinal absorption and brain entry of xenobiotics that are P-gp substrates can be significantly enhanced by the coadministration of P-gp inhibitors such as PSC833, GF120918 and verapamil (Mayer *et al*, 1997; Bardelmeijer *et al*, 2000; Nakagami *et al*, 2005). One issue of concern when attempting to evaluate the possible influence of a P-gp inhibitor on the disposition of a coadministered drug is its inhibitory potency, along with the local concentration achieved by the putative P-gp inhibitor. According to our results of the intracellular Rh123 accumulation in LLC-PK1/MDR1 cells, RSP and PALI showed significantly inhibitory effects on P-gp activity at and above the concentrations of 1 and 50 μ M, respectively. After oral administration at typical therapeutic doses in rats, the mean peak plasma concentrations of both RSP and PALI were approximately 0.4 μ M (Aravagiri *et al*, 1998). Therefore, RSP, rather than PALI, may be more likely to affect the disposition of coadministered P-gp substrates.

It is recognized that P-gp is highly expressed in the liver and kidney. Sufficient inhibition of P-gp function can result in the delay of hepatic and renal clearance of P-gp substrates (Slapak *et al*, 2001; Pinto *et al*, 2005). The ratio of liver and kidney to plasma concentration of RSP was 22.3 and 14.3, whereas that of PALI was 67.5 and 47.1, respectively, in an animal model (Aravagiri and Marder, 2002). This significant tissue accumulation suggests that RSP and PALI may influence the pharmacokinetics of P-gp substrates through inhibition of P-gp in the liver and kidney. This issue has not yet been addressed in human studies.

The influence of a P-gp inhibitor on P-gp function within the BBB is a consequence of the inhibitor's potency, its plasma concentration, and its accumulation in BMECs, which form the BBB. Considering the relatively low plasma concentration of RSP, it is difficult to determine from the present experiments whether RSP could exhibit an inhibitory effect on P-gp within the BBB under usual clinical circumstances. Interestingly, our recent investigations have indicated that RSP significantly increased brain concentrations of the antidepressant sertraline and its principal metabolite desmethylsertraline in mice without altering their plasma concentrations at 1 h after i.p. injection (Wang *et al*, 2006a). Sertraline and desmethylsertraline have previously been reported to be P-gp inhibitors (Weiss *et al*, 2003). In addition, based upon a P-gp ATPase activity assay, our recent study indicated that sertraline and desmethylsertraline had high affinity for P-gp (Wang *et al*, 2006b). The V_{max}/K_m values of sertraline (1.6) and desmethylsertraline (1.4) were comparable with that of the positive control P-gp substrate verapamil (1.7) indicating both compounds are potential P-gp substrates. It would be a reasonable assumption that the increases of sertraline and desmethylsertraline concentrations within the brain are the result of inhibition of P-gp in BBB after coadministration of RSP. Although our data demonstrated that both RSP and PALI are P-gp inhibitors *in vitro*, the clinical relevance of P-gp inhibition by RSP and PALI remains to be determined because of the lack of clinical data on P-gp-mediated drug

interactions in humans involving RSP and PALI, and the intrinsic limitation of the relevance *in vitro* and animal experiments.

Of considerable theoretical interest is whether RSP, as a P-gp inhibitor, has an effect on the brain entry of its principal active metabolite and P-gp substrate PALI. Our previous work showed that the increase of brain-to-plasma ratio of PALI compared to RSP was greater in P-gp knockout mice than control mice (Wang *et al*, 2004a). Although both these compounds are P-gp substrates, the added capability of RSP to inhibit P-gp at the level of the BBB suggests a potential for enhancing the entry of PALI into the central nervous system when PALI is formed following the oral administration of RSP. Such an effect would not be present if PALI was administered as a preformed metabolite in the absence of RSP. Recognition of such relationships between drugs and their metabolites may help design studies to determine effective doses and explain observed differences in pharmacokinetic or pharmacodynamic effects between metabolites formed systemically or developed as separate therapeutic agents.

The mechanistic basis of P-gp transport and inhibition has been intensively studied for many years. Several hypotheses have been developed in an effort to explain the molecular mechanism of interaction of P-gp and its substrates or inhibitors. However, owing to multiple drug binding sites on P-gp, the development of a universally accepted model for reconciling the data from various laboratories remains a challenge. It has been demonstrated that there is a minimum of four drug binding sites on P-gp. These sites can be divided into two categories: transport sites, at which translocation of drug across the cellular membrane can occur, and regulatory sites, which modify P-gp function (Martin *et al*, 2000). In addition, some agents can inhibit P-gp activity by decreasing intracellular ATP supply and inhibiting P-gp ATPase activity (Batrakova *et al*, 2001). Considering the fact that both RSP and PALI appear to be P-gp substrates as well as inhibitors, competition with other substrates for binding to P-gp is a possible mechanism of their P-gp inhibition. However, other mechanisms cannot be excluded and further studies are needed to elucidate the molecular basis of RSP and PALI interactions with P-gp.

ACKNOWLEDGEMENTS

This work was supported by NIH grant MH071811-02A1.

REFERENCES

- Abbott NJ, Hughes CC, Revest PA, Greenwood J (1992). Development and characterisation of a rat brain capillary endothelial culture: towards an *in vitro* blood-brain barrier. *J Cell Sci* 103(Part 1): 23–37.
- Aquilante CL, Letrent SP, Pollack GM, Brouwer KL (2000). Increased brain P-glycoprotein in morphine tolerant rats. *Life Sci* 66: PL47–PL51.
- Aravagiri M, Marder SR (2002). Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. *Psychopharmacology (Berlin)* 159: 424–431.
- Aravagiri M, Marder SR, Wirshing D, Wirshing WC (1998). Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. *Pharmacopsychiatry* 31: 102–109.
- Ayrton A, Morgan P (2001). Role of transport proteins in drug absorption, distribution and excretion. *Xenobiotica* 31: 469–497.
- Bachmeier CJ, Miller DW (2005). A fluorometric screening assay for drug efflux transporter activity in the blood-brain barrier. *Pharm Res* 22: 113–121.
- Balayssac D, Authier N, Cayre A, Coudore F (2005). Does inhibition of P-glycoprotein lead to drug-drug interactions? *Toxicol Lett* 156: 319–329.
- Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH *et al* (2000). Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. *Clin Cancer Res* 6: 4416–4421.
- Batrakova EV, Li S, Vinogradov SV, Alakhov VY, Miller DW, Kabanov AV (2001). Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. *J Pharmacol Exp Ther* 299: 483–493.
- Bendayan R, Lee G, Bendayan M (2002). Functional expression and localization of P-glycoprotein at the blood brain barrier. *Microsc Res Tech* 57: 365–380.
- Benet LZ, Izumi T, Zhang Y, Silverman JA, Wachter VJ (1999). Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. *J Control Release* 62: 25–31.
- Boulton DW, DeVane CL, Liston HL, Markowitz JS (2002). *In vitro* P-glycoprotein affinity for atypical and conventional antipsychotics. *Life Sci* 71: 163–169.
- Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR *et al* (1989). Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. *Proc Natl Acad Sci USA* 86: 695–698.
- DeVane CL, Markowitz JS (2000). Drugs as substrates of metabolic enzymes: antipsychotics. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M (eds). *Metabolic Drug Interactions*. Lippincott-Raven Press: Philadelphia, PA. pp 245–258.
- Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E *et al* (2005). The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. *Drug Metab Dispos* 33: 165–174.
- Fardel O, Morel F, Guillouzo A (1993). P-glycoprotein expression in human, mouse, hamster and rat hepatocytes in primary culture. *Carcinogenesis* 14: 781–783.
- Gatmaitan ZC, Arias IM (1993). Structure and function of P-glycoprotein in normal liver and small intestine. *Adv Pharmacol* 24: 77–97.
- Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH (1993). Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. *J Biol Chem* 268: 14991–14997.
- Kharasch ED, Hoffer C, Whittington D (2004). The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. *Br J Clin Pharmacol* 57: 600–610.
- Kwei GY, Alvaro RF, Chen Q, Jenkins HJ, Hop CE, Keohane CA *et al* (1999). Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. *Drug Metab Dispos* 27: 581–587.
- Lieberman DM, Reithmeier RA, Ling V, Charuk JH, Goldberg H, Skorecki KL (1989). Identification of P-glycoprotein in renal brush border membranes. *Biochem Biophys Res Commun* 162: 244–252.
- Lin JH (2003). Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. *Adv Drug Deliv Rev* 55: 53–81.

- Loscher W, Potschka H (2005). Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. *Prog Neurobiol* **76**: 22–76.
- Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ *et al* (2002). Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. *J Pharmacol Exp Ther* **303**: 1029–1037.
- Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R (2000). Communication between multiple drug binding sites on P-glycoprotein. *Mol Pharmacol* **58**: 624–632.
- Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH (1997). Full blockade of intestinal P-glycoprotein and extensive inhibition of blood–brain barrier P-glycoprotein by oral treatment of mice with PSC833. *J Clin Invest* **100**: 2430–2436.
- Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y (2003). Impact of drug transporter studies on drug discovery and development. *Pharmacol Rev* **55**: 425–461.
- Nakagami T, Yasui-Furukori N, Saito M, Tateishi T, Kaneo S (2005). Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: *in vivo* evidence of involvement of P-glycoprotein in risperidone disposition. *Clin Pharmacol Ther* **78**: 43–51.
- Pinto N, Halachmi N, Verjee Z, Woodland C, Klein J, Koren G (2005). Ontogeny of renal P-glycoprotein expression in mice: correlation with digoxin renal clearance. *Pediatr Res* **58**: 1284–1289.
- Sadeque AJ, Wandel C, He H, Shah S, Wood AJ (2000). Increased drug delivery to the brain by P-glycoprotein inhibition. *Clin Pharmacol Ther* **68**: 231–237.
- Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS *et al* (1996). Risperidone compared with new and reference antipsychotic drugs: *in vitro* and *in vivo* receptor binding. *Psychopharmacology (Berlin)* **124**: 57–73.
- Schotte A, Janssen PF, Megens AA, Leysen JE (1993). Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured *ex vivo* by quantitative autoradiography. *Brain Res* **631**: 191–202.
- Seeman P (2005). An update of fast-off dopamine D2 atypical antipsychotics. *Am J Psychiatry* **162**: 1984–1985.
- Slapak CA, Dahlheimer J, Piwnica-Worms D (2001). Reversal of multidrug resistance with LY335979: functional analysis of P-glycoprotein-mediated transport activity and its modulation *in vivo*. *J Clin Pharmacol* **41**(Suppl): 29S–38S.
- Smit JW, Weert B, Schinkel AH, Meijer DK (1998). Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs. *J Pharmacol Exp Ther* **286**: 321–327.
- Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK *et al* (1997). Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. *Proc Natl Acad Sci USA* **94**: 2031–2035.
- Terasaki T, Ohtsuki S, Hori S, Takanaga H, Nakashima E, Hosoya K (2003). New approaches to *in vitro* models of blood–brain barrier drug transport. *Drug Discov Today* **8**: 944–954.
- van Bree JB, de Boer AG, Danhof M, Ginsel LA, Breimer DD (1988). Characterization of an ‘*in vitro*’ blood–brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. *J Pharmacol Exp Ther* **247**: 1233–1239.
- van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD (2000). Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. *Eur J Pharm Sci* **11**: 207–214.
- Wang JS, DeVane CL, Gibson BB, Donovan JL, Markowitz JS, Zhu HJ (2006a). Population pharmacokinetic analysis of drug–drug interactions among risperidone, bupropion, and sertraline in CFI mice. *Psychopharmacology (Berlin)* **183**: 490–499.
- Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL (2004a). The brain entry of risperidone and 9-hydroxy-risperidone is greatly limited by P-glycoprotein. *Int J Neuro-psychopharmacol* **7**: 415–419.
- Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL (2004b). Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood–brain barrier of Abcb1a gene knockout mice. *Psychopharmacology (Berlin)* **173**: 132–138.
- Wang JS, Taylor R, Ruan Y, Donovan JL, Markowitz JS, Lindsay De Vane C (2004c). Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. *Neuropsychopharmacology* **29**: 551–557.
- Wang JS, Zhu HJ, Gibson BB, Donovan JL, Markowitz JS, DeVane CL (2006b). Sertraline and its metabolite desmethylsertraline, but not bupropion or its major metabolite, have high affinity for P-glycoprotein. *Clin Pharmacol Ther* **79**: P16.
- Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE (2003). Inhibition of P-glycoprotein by newer antidepressants. *J Pharmacol Exp Ther* **305**: 197–204.